CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 523 enrolled
Drug / intervention
risperidonedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00249132
NCT00249132Phase 3Completed
CompareCT.gov

Risperidone Versus Haloperidol Versus Placebo in the Treatment of Chronic Schizophrenia

Janssen, LP·interventional·Posted Nov 7, 2005·Updated Feb 11, 2011

In Brief

A Phase 3 clinical trial evaluating risperidone for Schizophrenia and Psychotic Disorders. Completed, enrolled 523 participants.

Detailed Summary

The purpose of the study is to evaluate the effectiveness and safety of different doses of risperidone (an antipsychotic medication) compared with placebo and with a fixed 20 mg/day dose of a standard antipsychotic, haloperidol, in patients with chronic schizophrenia.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia, Psychotic Disorders
Countries--
Collaborators--

Timeline

Phase 3CompletedFinished
1991199219931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 7, 2005
Study CompletionJul 1, 1991
TodayJul 2, 2026
Posted 20.7 years ago

Interventions

risperidonedrug